After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses 1 . As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vaccines have shown limited promise in the treatment of patients with advanced cancers 2-4 including glioblastoma [5] [6] [7] , the factors dictating DC vaccine efficacy remain poorly understood. Here we show that pre-conditioning the vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumour-antigen-specific DCs. To assess the effect of vaccine site pre-conditioning in humans, we randomized patients with glioblastoma to pre-conditioning with either mature DCs 8 or Td unilaterally before bilateral vaccination with DCs pulsed with Cytomegalovirus phosphoprotein 65 (pp65) RNA. We and other laboratories have shown that pp65 is expressed in more than 90% of glioblastoma specimens but not in surrounding normal brain [9] [10] [11] [12] , providing an unparalleled opportunity to subvert this viral protein as a tumour-specific target. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumour growth in a manner dependent on the chemokine CCL3. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen may represent a viable strategy to improve anti-tumour immunotherapy.
, Roger E. McLendon 1, 3 , David A. Reardon 1, 2 , James J. Vredenburgh 1, 2 , Darell D. Bigner 1, 2, 3 & John H. Sampson 1, 2, 3, 5, 8 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses 1 . As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vaccines have shown limited promise in the treatment of patients with advanced cancers [2] [3] [4] including glioblastoma [5] [6] [7] , the factors dictating DC vaccine efficacy remain poorly understood. Here we show that pre-conditioning the vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumour-antigen-specific DCs. To assess the effect of vaccine site pre-conditioning in humans, we randomized patients with glioblastoma to pre-conditioning with either mature DCs 8 or Td unilaterally before bilateral vaccination with DCs pulsed with Cytomegalovirus phosphoprotein 65 (pp65) RNA. We and other laboratories have shown that pp65 is expressed in more than 90% of glioblastoma specimens but not in surrounding normal brain [9] [10] [11] [12] , providing an unparalleled opportunity to subvert this viral protein as a tumour-specific target. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumour growth in a manner dependent on the chemokine CCL3. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen may represent a viable strategy to improve anti-tumour immunotherapy.
To evaluate the influence of vaccine site pre-conditioning on DC migration clinically, we conducted a randomized and blinded clinical trial in newly diagnosed glioblastoma (GBM) (Extended Data Fig. 1 ). A total of 13 patients consented to this trial but only 12 were randomized as 1 progressed before randomization (Extended Data Table 1 ). Patients were randomized to unilateral vaccine site pre-conditioning with unpulsed, autologous DCs 8 or Td, on the basis of our hypothesis that it would induce inflammation at the vaccine site 13 . The accumulation of injected DCs in vaccine site-draining lymph nodes (VDLNs) was significantly greater in patients given Td (Fig. 1a) . Moreover, Td-treated patients also showed a significant increase in both progression-free survival (Fig. 1b ) and overall survival (Fig. 1c ) compared to DC-treated patients. From the time of diagnosis, patients in the DC cohort had median progressionfree and overall survivals of 10.8 and 18.5 months, respectively. Thus, the median progression-free and overall survivals for the DC cohort were consistent with patients treated with the standard of care 14 . Three censored patients from the Td cohort did not progress and were alive at the time of survival analysis (.36.6 months). Overall, these prognostic factors varied across both treatment groups as expected in a small clinical trial. However, there was no discernible trend across prognostic factors that would suggest that these factors alone account for the observed differences in survival between cohorts. Using both a previously published recursive partition analysis 15 and the European Organization for Research and Treatment of Cancer (EORTC) nomogram 16 for predicting outcome of patients with GBM, Td-treated patients exceeded expected survival times by a far greater degree than did DC-treated patients in both cases by nearly the same amount (Extended Data Table 1 ). The vaccine responses in long-term survivors varied in durability, but pp65-specific immune responses were detectable for several months in all long-term survivors. An increase in pp65-specific interferon-c spot-forming units from baseline did correlate with overall survival, and the two long-term survivors for which samples were available had the highest increases in pp65-specific immune responses after vaccination. In addition, we observed a notable association between DC migration to the VDLNs and progression-free and overall survival (Fig. 1d ) in patients with GBM receiving pp65 RNA-pulsed DC vaccines.
To validate these clinical results and understand the mechanistic underpinnings, we performed analogous studies in a mouse model. Vaccine sites of Td-immune mice were pre-conditioned with Td and then received a bilateral vaccine of ovalbumin (OVA) RNA-pulsed DCs. In parallel to our clinical findings, Td-immune mice receiving Td preconditioning had a threefold increase in DCs within the afferent inguinal lymph nodes (Fig. 2a) . This effect was attributable to Td-specific recall responses as mice not primed with Td (Td-naive mice) did not display any increased DC migration to VDLNs (Fig. 2b) . Vaccination and preconditioning with other CD4-dependent protein antigens also increased DC migration, suggesting that this may be a generalizable phenomenon (Extended Data Fig. 2 ). Subsequent studies performed in Td-treated mice demonstrated that only selective depletion of CD4
1 T cells abrogated the increase in DC migration (Fig. 2c) . The effect of enhanced migration was also transferable to naive mice administered Td-activated CD4 1 T cells (Fig. 2d ). In patients with GBM randomized to unilateral Td pre-conditioning ( Fig. 2e ) and in mice (Fig. 2f) , we observed an increased uptake of 111 In-labelled DCs in bilateral lymph nodes, suggesting that Td preconditioning increased DC migration through systemic mediators. Subsequent experiments revealed that Td-activated CD4
1 T cells administered systemically in naive mice were also sufficient to increase bilateral DC migration (Extended Data Fig. 3 ). Vaccine site pre-conditioning with unpulsed DCs or TNF-a (ref. 8) only increased DC migration ipsilaterally (Extended Data Fig. 4a, b) .
On the basis of our observations that Td recall responses could induce bilateral DC migration and that systemic administration of Td-activated
CD4
1 T cells was sufficient to recapitulate the increased DC migration, we sought to examine the induction of CD4-dependent inflammatory mediators in the serum of patients and mice after a recall response with Td pre-conditioning. CCL3 was the only chemokine or cytokine to be increased in both patients and mice and had the greatest fold increase of all chemokines in the serum of both after Td pre-conditioning ( Fig. 3a and Extended Data Fig. 5a-d) .
To identify the site of the CCL3 production, we assayed the preconditioning sites in mice and found high concentrations of this chemokine only unilaterally at the site of Td pre-conditioning (Extended Data Fig. 6a ). Subsequent experiments showed that CCL3 upregulation in the skin was dependent on the induction of the Td recall response (Extended Data Fig. 6b ) and was significantly reduced by CD4
1 T-cell depletion (Extended Data Fig. 6c ). Induction of CCL3 by Td preconditioning remained increased over time compared to mice lacking Td recall responses (Extended Data Fig. 6d ).
To evaluate the importance of CCL3 in mediating DC trafficking to VDLNs in vivo, we immunized and boosted Ccl3 2/2 mice with Td as described above and found that the migration of injected DCs to VDLNs in Ccl3 2/2 mice was significantly lower than in wild-type Td pre-conditioned mice (Fig. 3b, 
top). Endogenous migration experiments revealed that resident Langerhans cells also did not migrate as efficiently in Ccl3
2/2 hosts after Td pre-conditioning (Extended Data Fig. 7 ). To address the possibility that Td priming may have failed in Ccl3 2/2 mice owing to some earlier role of CCL3, we compared the CD4 T-celldependent immune responses to Td in both wild-type and Ccl3
2/2
hosts and found no differences in the ability of these two strains to mount anti-tetanus immune responses after Td priming and boosting (Extended Data Fig. 8 ).
Our studies demonstrated that CD4 1 T cells activated by the Td recall response were sufficient to induce increased DC migration in naive mice (Fig. 2d) . However, Td-activated CD4
1 T cells could not rescue the limited DC migration in Ccl3 2/2 hosts indicating that activated T cells were necessary, but not sufficient to increase DC migration ( 1 T cells to increase DC migration to VDLNs. a, Control inguinal (n 5 5 mice) versus Td inguinal (n 5 5 mice); two sample t-test, P 5 0.0001; Td popliteal (n 5 5 mice) versus Td inguinal, paired t-test, P 5 0.014. b, Mice primed and boosted with saline (primary Td, n 5 6) or Td (control and recall Td, n 5 6) with Td (primary and recall Td) or saline (control) pre-conditioning; one-way analysis of variance (ANOVA), P 5 0.004; post-hoc Tukey t-test, control versus recall Td, P 5 0.006; primary Td versus recall Td, P 5 0.011. c, DC migration in depleted Td-immunized mice (n 5 5); one-way ANOVA, P , 0.0001; post-hoc Tukey t-test, Td versus CD4, P 5 0.005; Td versus CD8, CD19 or NK1.1, P . 0.05. d, DC migration after CD4 1 transfer (n 5 4 mice); one-way ANOVA, P , 0.0001; post-hoc Tukey t-test, Td-activated CD4 1 T cells (CD4 act ) versus CD4 naive , P , 0.05; control versus CD4 naive , P . 0.05; Td versus CD4 act , P . 0.05. e, Patient (e) and mouse (f) iLN ipsilateral (n 5 6) and contralateral (n 5 6) to pre-conditioning; paired t-test, P 5 0.28 (e) and P 5 0.37 (f). a-d and f are representative of four experiments; mean 6 s.e.m. Data in a-d denote biological replicates of individual right and left iLN or lymph nodes ipsilateral to Td/saline for popliteal and GFP 2 groups.
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DC migration in Ccl3 2/2 mice, but only when the Td recall responses were induced (Fig. 3c) , indicating that the ability of Td pre-conditioning to increase DC migration to VDLNs was dependent on both CD4 1 recall responses and host-derived CCL3.
Alterations in CCL21 expression along the lymphatic endothelium in the skin take place in the context of inflammation and have been associated with increased DC migration 8 . After Td pre-conditioning, higher levels of CCL21 in collected skin sites were detected in Td-treated wild-type mice compared to Ccl3 2/2 mice, and exogenous administration of CCL3 rescued the diminished levels of CCL21 at the vaccine sites of Ccl3 2/2 mice only in the context of Td recall responses (Extended Data Fig. 9a) , which paralleled the requirement of host CCL3 and Td recall responses for increased DC migration. Furthermore, Td preconditioning resulted in an increase in CCL21 within inguinal lymph nodes both ipsilateral and contralateral to the side of Td pre-conditioning (Extended Data Fig. 9b ). Although lymph nodes contain high basal amounts of CCL21, we found CCL21 levels in bilateral inguinal lymph nodes of Td-treated Ccl3 2/2 mice to be lower than that of wild-type mice. Meanwhile, reconstitution of CCL3 back into Ccl3 2/2 mice in conjunction with the induction of Td recall responses markedly increased the expression of CCL21 in VDLNs (Extended Data Fig. 9c) .
The apparent increase in progression-free and overall survival for Td treated-patients prompted us to determine whether Td pre-conditioning could inhibit tumour growth in a mouse subcutaneous tumour model in which B16F10 melanoma cells expressed OVA (B16-OVA). Pairwise comparisons revealed that tumour growth in Td plus OVA-DC mice was significantly delayed (Fig. 4a) in an antigen-dependent manner (Fig. 4b) . Td pre-conditioning in Ccl3 2/2 mice, as expected, was unable to inhibit tumour growth (Fig. 4c) . Similarly, plt (paucity of lymph node T cell) mice, which lack expression of CCL21 in the lymph nodes 17 , also failed to suppress tumour growth (Fig. 4d) , indicating that Tdenhancement of OVA-DC vaccines also required intact CCL21 expression in the host.
Results from our trial seem to demonstrate that the modulation of CMV-specific DCs with Td pre-conditioning increases their migratory capacity and may improve clinical outcomes in patients with GBM. Corroborating studies in mice support these claims and underline CCL3 as a novel and important mediator of increased DC migration to VDLNs, in addition to its described roles in DC precursor mobilization to peripheral sites of inflammation 18, 19 and in guiding naive CD8 1 localization to sites of DC-CD4
1 interactions in lymph nodes 20 . Our preclinical findings suggest that increased DC migration was only observed in the context of host CCL3 and Td recall responses. Similarly, we observed a slight increase in CCL21 skin and bilateral VDLN levels in the context of both host CCL3 and Td recall, which may have a role in DC homing to local lymph nodes. However, owing to the already high basal amount 
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of CCL21 chemokine in draining lymph nodes, it is possible that additional factors such as interactions between host CCL3 and CD4 1 recall T cells are the predominant contributors to the increased DC accumulation in VDLNs. Our findings also suggest that DC migration should be further investigated as a predictive biomarker for immunotherapy studies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Patient selection, demographics and clinical protocol. The clinical protocol and informed consent were approved by the US Food and Drug Administration and Institutional Review Board at Duke University. Adults with a newly diagnosed World Health Organization (WHO) grade IV GBM, who had a gross total resection and residual radiographic contrast enhancement on post-resection magnetic resonance imaging (MRI) not exceeding 1 cm in diameter in two perpendicular axial planes, and a Karnofsky performance scale score of $80, were eligible for the clinical study (FDA -IND-BB-12839, Duke IRB Pro00003877, NCT00639639). Histopathology of all specimens was initially read as GBM, but this diagnosis was re-confirmed by a second board-certified neuropathologist. Histological diagnosis included immunohistochemistry for MGMT protein expression. Benign endothelial cells staining positive for MGMT served as the internal control 21 . MGMT promoter methylation was performed by PCR. On the basis of published reports showing high expression of CMV viral proteins in .90% of GBM tumours [9] [10] [11] [12] , we elected not to include pp65 staining of tumour tissue as an eligibility criterion for this trial. All 13 patients on study received a gross total resection defined as .90% with residual contrast enhancement of ,1 cm 2 , and steroid doses could not exceed 2 mg day 21 of dexamethasone. No patients received intensity-modulated radiation therapy or had 5-aminolevulinic acid dye used during resection. Thereafter, all patients completed a 6-week course of conformal external beam radiotherapy to a dose of 60 Gy with concurrent temozolomide at a targeted daily dose of 75 mg m 22 day 21 . After completion of standard therapy, all patients underwent an MRI for evidence of progressive disease. Those with evidence of progressive disease or required steroid therapy in excess of physiological levels at the time of vaccination were replaced. A total of 13 patients were enrolled and randomized before the first cycle of standardof-care 5-day TMZ (200 mg m 22 day
21
), but one progressed before randomization. For each vaccine, 2 3 10 7 mature pp65 RNA-pulsed DCs in 0.4 ml of saline were given intradermally in the groin. The first vaccination occurred on day 21 6 2 of TMZ cycle 1. Although some patients (n 5 5) were also randomized to receive an autologous lymphocyte transfer, those patients did not show a significant improvement in progression-free or overall survival. Patients given autologous lymphocytes were additionally administered 3 3 10 7 cells kg 21 intravenously with acetaminophen (650 mg per os (po)) and Benadryl (25-50 mg po) given 30-60 min before infusion. The first three DC vaccines were given bi-weekly, and, at vaccine 4, patients were randomized to Td or unpulsed autologous DCs and received
111
Inlabelled DCs for migration studies. Vaccine 4 and additional monthly vaccines until tumour progression occurred on day 21 6 2 of successive TMZ cycles. A minimum of six cycles of adjuvant TMZ were required as per standard-of-care and continuation was at the discretion of the treating neurooncologist. Patients were monitored for treatment-related toxicity, and none of the patients experienced any vaccine or Td-related adverse events. Human autologous DC generation for vaccination and production of pp65-LAMP/A64 mRNA. DCs were generated using the method described previously 22 , and after collection the cells were frozen and assessed for contamination and lineage purity as previously published 23 . The 1.932-kilobase (kb) pp65 full-length cDNA insert was obtained from B. Britt and RNA was generated and transfected as previously reported 22 . Human DC migration studies. DC migration studies were done at the fourth vaccination. Patients were randomized by side to have one inguinal vaccination site pre-treated with either 1 3 10 6 unpulsed DCs or Td toxoid (1 flocculation unit (Lf)). Saline was administered on the contralateral side. Vaccination site pretreatment was done 6-24 h before DC vaccination. DCs were labelled with 10 mCi per 1 3 10 7 DC with 111 In (GE Healthcare) and divided equally in the two sites. Gamma camera images (GE Infinia Hawkeye) were taken immediately after injection and at 24 and 48 h after injection to compare 111 In-labelled DC migration from the inguinal injection sites to the inguinal lymph nodes. Progression-free and overall survival. The more recent response evaluation criteria in solid tumours (RECIST criteria) judge progression by measuring the longest one-dimensional diameter and determine progression by a 20% increase in this diameter 24 . Once progression is detected on MRI, other imaging modalities such as positron emission tomography and a stereotactic brain biopsy of the enhancing region are incorporated to aid in determining progression. A stereotactic brain biopsy or resection demonstrating recurrence defines clinical progression. Progression-free survival was defined as the time until radiographic or clinical progression and was censored at the last follow-up if the patient remained alive without disease progression. Overall survival was defined as the time until death and was censored at the last follow-up if the patient remained alive at the time of analysis. Progressionfree and overall survival for all patients were calculated from both the time of surgery and from randomization to vaccine site pre-conditioning. Mice. All animal experiments were performed according to Duke University Institutional Animal Care and Use Committee-approved protocols. Female C57BL/6 wild-type, OT-I transgenic mice, Ccl3
2/2
, and red fluorescent protein (RFP) and green fluorescent protein (GFP) transgenic mice (ubiquitin promoter) were obtained from the Jackson Laboratory and were bred under pathogen-free conditions at Duke University Medical Center. The plt strain was provided by M.D.G. and maintained at Duke University Medical Center. All mice were bred under pathogen-free conditions at Duke University Medical Center. Generation of mouse bone marrow-derived DCs, electroporation and phenotyping. Bone-marrow-derived DCs were generated from 6-8-week-old female C57BL/6 wild-type, RFP 1 or GFP 1 transgenic mice and pulsed with OVA RNA as previously described 25 . For phenotyping, anti-mouse phycoerythrin (PE)-conjugated CD11c (HL3), CD80 (16-10A1), CD86 (GL1), Ly-6G (1A8), MHC class II (I-A b ; AF6-120.1) and isotype controls (IgG1; G235-2356, IgG 2a ,k; R35-95) were from BD Pharmingen. Cells were washed, resuspended in PBS and 2% FBS, incubated at 4 uC for 30 min, and washed again before use. Vaccine site pre-conditioning and DC vaccination in mice. For Td immunization, female 6-8-week-old C57BL/6 mice received a primary intramuscular vaccine of Td toxoid (Sanofi Aventis; Decavac; 1 Lf, 100 ml) administered bilaterally into the quadriceps muscle (50 ml per leg). An intramuscular booster (0.5 Lf, 50 ml) was administered two weeks later. Vaccine site pre-conditioning with saline or Td toxoid (0.5 Lf) was given intradermally (i.d.) 2 weeks after the booster and randomized to the right or left groin site. Mouse IgG antibody responses to Td were measured by ELISA (Xpress Bio). Serum from immunized mice was collected 2 weeks after each immunization before the next booster vaccine. DCs were resuspended at 1 3 10 6 per 100 ml PBS (Gibco) and administered i.d. on both sides 0.8 cm from the groin crease 24 h after i.d. pre-conditioning. DCs injected in the groin ipsilateral to the Td pre-conditioning side were directly injected i.d. within the erythematous nodule produced by Td pre-conditioning. For recall response experiments using other protein antigen formulations, female 6-8-week-old C57BL/6 mice received a primary intramuscular vaccine of Prevnar 13 (Pfizer, Pneumococcal 13-valent conjugate vaccine, 1.32 mg, 100 ml) and Pedvax HIB (Merck, Haemophilus b conjugate vaccine, 1.5 mg, 100 ml) administered bilaterally into the quadriceps muscle (50 ml per leg). Vaccine site pre-conditioning with saline or the protein antigen (50 ml) was given i.d. 2 weeks later and randomized to the right or left groin site. DC vaccines were given 24 h later, and migration to lymph nodes was assessed 48 h later. As with Td pre-conditioning, DCs injected in the groin ipsilateral to the pre-conditioning side were directly injected i.d. within the erythematous nodule produced by those formulations. For comparisons of other pre-conditioning agents, female 6-8-weekold C57BL/6 mice received a unilateral dose of unpulsed, mature DCs (1 3 10 6 in 50 ml) or TNF-a (30 ng) administered i.d. at the groin site 24 h before DC vaccination. On the basis of the previous work using these pre-conditioning regimens, DC migration to bilateral inguinal lymph nodes was assessed 24 h later. For all other migration experiments, popliteal and inguinal lymph nodes were collected 48 h after DC vaccination and digested for flow cytometry. The percentage of migrating DCs was enumerated by gating on fluorescent DCs in wild-type VDLNs. DCs from wild-type (GFP 2 and RFP 2 ) mice as negative controls before gating on fluorescent DCs within VDLNs to account for background autofluorescent cells that may have appeared in the GFP channel. For in vivo DC migration, a sample size (three per group) was based on empirical evidence from previously published reports as the size necessary for adequate statistical analysis of lymph nodes sampled 26 . Depletion, adoptive transfer and CCL3 reconstitution. Female 6-8-week-old C57BL/6 mice were initially depleted of cellular subsets once daily (200 mg per mouse intraperitoneally) for 3 days before the first Td intramuscular immunization. Antimouse CD4 (GK1.5) and anti-CD8 (2.43) antibodies were purchased from American Type Culture Collection. Anti-mouse NK1.1 (PK136) and anti-CD19 (2D5) and control isotype depleting antibodies (IgG2a (2A3) and IgG2b (LTF-2)) were from BioXCell. Maintenance doses of depletion antibodies were administered at 3-day intervals (200 mg intraperitoneally) until vaccine site pre-conditioning with Td 2 weeks later. For adoptive transfer experiments, Td-activated CD4 1 T cells (CD4 act ) were induced in donor female 6-8-week-old C57BL/6 mice. Mice were primed (1 Lf, 100 ml) and boosted (0.5 Lf, 50 ml) intramuscular with Td 2 weeks apart. Three days after the i.d. Td pre-conditioning, donor inguinal lymph nodes, skin injection sites, and spleens were collected and processed for negative isolation of CD4 1 T cells (Miltenyi Biotec). Complementary sites from naive mice were collected simultaneously and processed for negative isolation of CD4 1 T cells (CD4 naive ). A final dose of 6 3 10 6 CD4 1 T cells were administered intravenously into recipient mice two days before i.d. vaccination with RFP 1 DCs. For CCL3 reconstitution in Ccl3 2/2 hosts, recombinant mouse CCL3 (R&D Systems) was administered intravenously into the tail vein (10 mg per mouse) 12 h before vaccination with RFP 
DCs. Ccl3
2/2 mice that were Td-immune were given recombinant CCL3 12 h after Td pre-conditioning at the vaccine site. Tumour implantation experiments. For tumour implantation experiments, B16F10-OVA cells were grown as previously published 27 and injected subcutaneously at a concentration of 2 LETTER RESEARCH
